No Data
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $37
Monopar Therapeutics Price Target Raised to $37 From $9 at JonesResearch
Monopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson's Disease Treatment
Monopar Therapeutics Analyst Ratings
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $22
Transformative Licensing Acquisition Drives Buy Rating for Monopar Therapeutics
No Data
No Data
